TNGX Insider Trading

Insider Ownership Percentage: 6.30%
Insider Buying (Last 12 Months): $74,000.00
Insider Selling (Last 12 Months): $38,241,798.58

Tango Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Tango Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M$0$10MTotal Insider BuyingTotal Insider Selling

Tango Therapeutics Share Price & Price History

Current Price: $1.29
Price Change: Price Increase of +0.01 (0.78%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for TNGX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$1.29Closing price on 04/18/25:

SEC Filings (Institutional Ownership Changes) for Tango Therapeutics (NASDAQ:TNGX)

78.99% of Tango Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TNGX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$62kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40M-$20M$0$20M$40MTotal InflowsTotal Outflows
Tango Therapeutics logo
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Read More on Tango Therapeutics

Today's Range

Now: $1.29
Low: $1.27
High: $1.33

50 Day Range

MA: $1.79
Low: $1.21
High: $2.51

52 Week Range

Now: $1.29
Low: $1.11
High: $12.02

Volume

467,141 shs

Average Volume

1,072,447 shs

Market Capitalization

$139.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Who are the company insiders with the largest holdings of Tango Therapeutics?

Tango Therapeutics' top insider shareholders include:
  1. Rock Ventures Iv LP Third (Major Shareholder)
  2. Boxer Capital, Llc (Insider)
  3. Boxer Capital Management, Llc (Insider)
  4. Barbara Weber (CEO)
  5. Mva Investors, Llc (Insider)
  6. Adam Crystal (Insider)
  7. Daniella Beckman (CFO)
  8. Douglas Barry (General Counsel)
  9. Mace Rothenberg (Director)
Learn More about top insider investors at Tango Therapeutics.

Who are the major institutional investors of Tango Therapeutics?

Tango Therapeutics' top institutional investors include:
  1. Exchange Traded Concepts LLC — 0.06%
Learn More about top institutional investors of Tango Therapeutics stock.

Which institutional investors are buying Tango Therapeutics stock?

During the previous quarter, TNGX stock was acquired by institutional investors including:
  1. Exchange Traded Concepts LLC
In the last year, these company insiders have bought Tango Therapeutics stock:
  1. Rock Ventures Iv LP Third (Major Shareholder)
  2. Boxer Capital, Llc (Insider)
Learn More investors buying Tango Therapeutics stock.